Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 4/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416921 | 0.91 | KDM4E (0.38) | PSDHTR1AKDM4EALDH1A1AOC3 | |
| SCHEMBL4416955 | 0.89 | VCP (0.34) | MERTKAXLTYRO3JAK2JAK1 | |
| SCHEMBL7110842 | 0.84 | SYK (0.39) | MERTKTYRO3FLT3GAS6SYK | |
| SCHEMBL4416954 | 0.82 | CDK1 (0.37) | PSDHTR1AKDM4EALDH1A1AOC3 | |
| SCHEMBL4425944 | 0.82 | AXL (0.39) | MERTKAXLTYRO3JAK2JAK1 | |
| SCHEMBL4418202 | 0.82 | ALDH1A1 (0.45) | HTR1AKDM4EALDH1A1 | |
| SCHEMBL4415007 | 0.77 | KMT2A (0.45) | SYKJAK2JAK1JAK3GPR6 | |
| SCHEMBL4417168 | 0.75 | GRM2 (0.39) | MERTKAXLJAK2JAK1JAK3 | |
| SCHEMBL4416527 | 0.74 | GRM2 (0.41) | KDM4EALDH1A1AOC3 | |
| SCHEMBL4412341 | 0.74 | ALDH1A1 (0.49) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397351-B1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| CN-1245391-C | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | HOFFMANN LA ROCHE (CH) | 2006-03-15 | — | — | CN | disclosed |
| CN-1512988-A | Pyrimidine, Triazine and pyrazine derivatives as glutamate receptors | - | 2004-07-14 | — | — | CN | disclosed |
| EP-1397351-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-17 | — | — | EP | disclosed |
| US-6673795-B2 | SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | US | disclosed |
| WO-2002098864-A1 | PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060466-A1 | Pyrimidine, pyrazine and triazine derivatives | P2RX5, IL5, P2RX2 | MERTK 4106/4885AXL 3384/4885TYRO3 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.